PDUFA Date

Telix's PET imaging agent TLX101-Px faces Sept. 11 FDA decision for glioma

The NDA for TLX101-Px, an F-18 PET tracer to distinguish tumor regrowth from treatment effect in glioma, carries Fast Track and Orphan Drug status ahead of its September 11 PDUFA date.

By AppliedXLJuly 13, 2026Trial NCT06743100

Executive Summary

The FDA is set to rule by mid-September on whether an F-18 PET imaging agent can help doctors tell tumor regrowth apart from treatment-related brain changes in glioma, a distinction that current MRI often cannot make cleanly.
The application carries two positive regulatory signals, Fast Track and Orphan Drug designation, though neither guarantees the outcome of the review.
No other program shares this agent's target or diagnostic mechanism in glioma, leaving it without a direct precedent to benchmark the FDA's likely bar against.
An approval would also validate the underlying targeting biology behind the sponsor's separate, later-stage therapeutic candidate for the same patient population.

The decision

The FDA accepted Telix Pharmaceuticals Limited's New Drug Application for TLX101-Px, also known as Pixclara or Floretyrosine F 18, in April 2026 and assigned a PDUFA goal date of September 11, 2026. The drug is a PET imaging agent that targets the LAT1 and LAT2 amino acid transporters, membrane proteins that are upregulated in tumor tissue, to help clinicians distinguish recurrent or progressive glioma from pseudoprogression, brain changes caused by prior radiation or other treatment that mimic tumor regrowth on standard MRI. The trial supporting the program, NCT06743100, is an expanded access study open to pediatric and adult patients with indeterminate MRI findings after glioma treatment, and it is registered as non-registrational in design. Telix+1

Probability of Success

Endpoint Met2%

Completes0%

Clinical Significance2%

Regulatory59%

What the decision turns on

TLX101-Px has been granted Fast Track and Orphan Drug designations by the FDA for this indication. Fast Track allows more frequent FDA interaction and rolling review; Orphan Drug status confers market exclusivity and signals a rare-disease unmet need, but neither designation predicts whether the agency ultimately approves the application. The company's own release states plainly that TLX101-Px has not received marketing authorization in any jurisdiction to date. No primary endpoint data, imaging accuracy figures, or comparator performance for the pivotal evidence package supporting the NDA have posted publicly. Telix

The competitive frame

No competing trial shares TLX101-Px's LAT1/LAT2 target or its specific diagnostic use in distinguishing glioma recurrence from treatment effect. The nearest precedents in glioma imaging and treatment monitoring use different modalities and different targets entirely, including Ga-68-DOTATATE (an SSTR2-targeted PET agent tested in meningioma), a Novartis LAT-unrelated radioligand in glioblastoma, and device- or small-molecule-based approaches such as GammaTile and IDH1 inhibitor safusidenib, none of which address the same MRI-ambiguity problem this agent targets. That isolation means the FDA's review has no directly analogous approved diagnostic to benchmark against in this indication; the bar the data package must clear is whatever performance threshold FDA sets internally for a first-of-its-kind PET agent in this specific clinical question, since no validated imaging standard exists for separating pseudoprogression from true progression at the population level captured by this trial's eligibility criteria. NCT06743100

Strategic readthrough

TLX101-Px functions as a potential patient-selection and response-assessment companion for Telix's separate LAT1-targeting therapeutic candidate, TLX101-Tx (131I-iodofalan), which is in the pivotal IPAX-BrIGHT trial in recurrent glioblastoma. An approval for the diagnostic agent would extend beyond its own label: it would put a regulatory stamp on the LAT1/LAT2 targeting rationale that underlies the therapeutic program, ahead of that trial's own readout. Telix also disclosed a June 2026 memorandum of understanding with United Imaging Healthcare North America to explore integrating TLX101-Px workflows with United Imaging's scanner platforms in the United States, an early step toward commercial deployment infrastructure that assumes approval. Telix

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.